Emcure Pharmaceuticals Ltd. reported a robust performance for the quarter ended September 30, 2025, driven by double-digit growth across both domestic and international markets. The company’s consolidated revenue from operations rose 13.4 per cent year-on-year (YoY) to ₹2,270 crore, while profit after tax (PAT) surged 24.7 per cent to ₹251 crore.

EBITDA grew 15.2 per cent YoY to ₹439 crore, with margins improving slightly to 19.3 per cent. Profit before tax (PBT) rose 24.9 per cent YoY to ₹341 crore.

Emcure’s domestic business delivered ₹1,031 crore in sales, marking a 10.6 per cent YoY rise, led by strong growth across key therapies and new product initiatives. The international business posted an even stronger 15.8 per cent YoY growth, reaching ₹1,238 crore, supported by solid performa

See Full Page